<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02706249</url>
  </required_header>
  <id_info>
    <org_study_id>15-547</org_study_id>
    <nct_id>NCT02706249</nct_id>
  </id_info>
  <brief_title>Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients</brief_title>
  <official_title>A Randomized, Phase II Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hospitalized patients with histologically or cytologically confirmed diagnosis of solid tumor
      malignancy, lymphoma, or multiple myeloma and who are at high risk for a venous
      thromboembolism will be randomized to standard dose versus intermediate dose enoxaparin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a phase II trial, high risk hospitalized cancer patients will be enrolled and randomized
      to standard dose enoxaparin versus intermediate dose (weight adjusted) enoxaparin
      thromboprophylaxis. Study subjects will be administered enoxaparin during hospitalization in
      a double-blinded manner. Following completion of 14 days, the study arms will be unblinded
      and lower extremity ultrasound performed on the standard dose enoxaparin arm in order to more
      accurately determine the overall cumulative incidence of thrombosis in this group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of VTE in standard dose enoxaparin arm</measure>
    <time_frame>17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of major hemorrhage in weight-adjusted enoxaparin arm and standard dose enoxaparin arm</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of symptomatic VTE</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Venous Thormboembolism</condition>
  <arm_group>
    <arm_group_label>A: Standard Dose Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Enoxaparin 40 mg subcutaneously once daily. On study Enoxaparin will be administered for up 14 days during hospitalization.
After the day 14 assessment, treatment arms will be un-blinded in order to appropriately schedule a bilateral lower extremity ultrasound for participants enrolled onto Arm A at day 17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Weight Adjusted Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Enoxaparin at 1mg/kg subcutaneously once daily with maximum dose of 100 mg daily. Participants who weigh more than 100kg will be capped at 100mg.
On study Enoxaparin will be administered for up 14 days during hospitalization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <arm_group_label>A: Standard Dose Enoxaparin</arm_group_label>
    <arm_group_label>B: Weight Adjusted Enoxaparin</arm_group_label>
    <other_name>Lovenox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have histologically or cytologically confirmed diagnosis of solid
             tumor malignancy, lymphoma or multiple myeloma.

          -  Cancer diagnosis or received treatment (chemotherapy or radiotherapy) for malignancy
             within the previous 6 months

          -  One or more Padua-based risk factor:

               -  History of previous venous thromboembolic event (excluding superficial vein
                  thrombosis)

               -  Reduced mobility (ECOG performance status 3 or 4, see Appendix A)

               -  Established hereditary thrombophilia (e.g. Factor V Leiden, G20210 prothrombin
                  mutation, protein C or S deficiency, antithrombin deficiency).

               -  Recent surgery within the last 30 days

               -  Age ≥ 70 years

               -  Congestive heart failure (NYHA class III or IV)

               -  Complicated respiratory insufficiency (defined as an increased requirement for
                  supplementary oxygen of at least 2L)

               -  Acute myocardial infarction or ischemic stroke

               -  Obesity (BMI ≥ 30)

               -  Receiving hormonal agents (e.g. tamoxifen, estrogen, testosterone)

               -  Acute infection (i.e. requiring antimicrobial therapy)

          -  Age ≥ 18 years

          -  Life expectancy of greater than 30 days

          -  Platelet count ≥ 100,000/mcL

          -  Creatinine &lt; 1.5 mg/dL or estimated creatinine clearance ≥ 50 mL/min/1.73 m2

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Weight between 50kg to 130 kg.

        Exclusion Criteria:

          -  History of allergic reactions attributed to heparin or low molecular weight heparin

          -  Active bleeding or otherwise considered high risk for hemorrhage (e.g. known acute
             gastrointestinal ulcer)

          -  Any history of significant hemorrhage (requiring hospitalization or transfusion)
             within the last 6 months (excluding hemorrhage during operative procedure).

          -  History of heparin induced Thrombocytopenia

          -  Presence of coagulopathy (PT or PTT&gt; 1.2 x upper limit of normal)

          -  Known diagnosis of disseminated intravascular coagulation

          -  Currently receiving therapeutic anticoagulant therapy or dual antiplatelet therapy
             (eg. aspirin and clopidogrel)

          -  Uncontrolled arterial hypertension (systolic blood pressure &gt; 200mmHg, diastolic
             &gt;110mmHg)

          -  Active peptic ulcer disease

          -  Bacterial Endocardititis

          -  Received any type of Pharmacologic Thromboprophylaxis (e.g. low molecular weight
             heparin or heparin) for &gt;48 hours during current hospitalization

          -  Known brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Zwicker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey Zwicker, MD</last_name>
    <phone>617-667-9299</phone>
    <email>jzwicker@bidmc.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Zwicker, MD</last_name>
      <phone>617-667-9299</phone>
      <email>jzwicker@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Zwicker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alok Khorana, MD</last_name>
      <phone>216-636-2690</phone>
      <email>Khorana@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Alok Khorana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2016</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jeffrey Zwicker, MD</investigator_full_name>
    <investigator_title>Jeffrey Zwicker, MD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

